Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS
Launched by ROYAN INSTITUTE · Jan 16, 2013
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
In this study our purpose is to evaluate the safety of intraventricular injection of bone marrow derived mesenchymal stem cell.the patients who are eligible,underwent bone marrow aspiration.after cell separation and preparation,the patients underwent mesenchymal stem cell intraventricular injection by stereotaxis.after injection he will be under observed in ICU to monitor the adverse events(allergic and neurological side effects).patients are followed 1th,3th ,6th and 12 months after injection and each time these parameters are checked:ALS-FRS,EMG-NCV,FVC,side effect check list.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age:18-65
- • both gender
- • duration of disease\<2 years
- • FVC\>40% ALS-FRS\>26
- Exclusion Criteria:
- • neurological and psychiatric concomitant disease
- • concomitant systemic disease
- • treatment with corticosteroid,Ig,immunosuppressive during 12 months.
About Royan Institute
The Royan Institute is a leading research organization dedicated to advancing the fields of reproductive health, stem cell biology, and regenerative medicine. Established to promote scientific innovation and clinical applications, the Institute focuses on translating cutting-edge research into therapeutic solutions. With a strong commitment to ethical practices and collaboration, Royan Institute conducts rigorous clinical trials aimed at improving patient outcomes and enhancing healthcare practices globally. Through its multidisciplinary approach and state-of-the-art facilities, the Institute strives to push the boundaries of medical science and contribute significantly to the understanding and treatment of complex health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Trial Officials
Hamid Gourabi, PhD
Study Chair
Head of Royan Institute
Nasser Aghdami, MD,PhD
Study Director
Head of Royan department of degenerative medicine,Head of Royan celltherapy center
Seyed Masoud Nabavi, MD
Study Director
Proffessor assistant of Shahed University
leila Arab, MD
Principal Investigator
Department of regenerative medicine,Royan Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials